Skip to main contentAI and Advanced
/
HALEOSLABS · NSEBSE SENSEX74,511.96+0.27%BSE |
NIFTY 5023,320.35+0.21%NSE |
NIFTY BANK56,297.3+0.43%NSE |
NIFTY IT28,633.85-1.79%NSE |
NIFTY AUTO27,237.15+0.29%NSE |
NIFTY FMCG45,519.05-0.12%NSE |
NIFTY PHARMA26,657+0.29%NSE |
NIFTY 50022,783.55+0.57%NSE |
HA
NSE · Equity shares · Biotechnology & Drugs85.40 · -1.07%
Haleos Labs HALEOSLABS
NSE:INR 1,558.7
BSE:INR 1,457.55
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for HALEOSLABS
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 1,473.3
Day rangeINR 1,490 — INR 1,538
52-week rangeINR 1,050.05 — INR 1,778.35
Volume394
Market cap475.82
P/E16.55
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)333.79
Net Income (INR Cr)17.31
Rev Growth (5 Year %)4.68
EPS Growth (5 Year %)5.01
P/E Ratio16.55
Book Value706.25
EPS57.26
Price/BV2.21Computed
Research path: Interpret Haleos Labs's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
HALEOSLABSHaleos Labs1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 454.41 | 389.99 | 390.52 |
| Cash Equivalents | 1.16 | Not available | Not available |
| Other Liabilities Total | 4.93 | 5.13 | 4.74 |
| Long Term Debt | 49.96 | 18.27 | 33.14 |
| Common Stock Total | 3.02 | 3.02 | 3.02 |
| Other Current Assets Total | 17.77 | 1.01 | 0.92 |
| Total Assets | 454.41 | 389.99 | 390.52 |
| Current Portof LT Debt/Capital Leases | 59.77 | 15.94 | 18.42 |
| Cash | 1.21 | 0.5 | 0.57 |
| Total Equity | 213.55 | 196.56 | 176.81 |
| Long Term Investments | 3.44 | 0.04 | 0.04 |
| Retained Earnings(Accumulated Deficit) | 210.52 | 193.54 | 173.79 |
| Total Common Shares Outstanding | 0.3 | 0.3 | 0.3 |
| Tangible Book Valueper Share Common Eq | 706.25 | 649.98 | 584.68 |
| Total Liabilities | 240.86 | 193.43 | 213.71 |
| Total Debt | 110.54 | 86.41 | 100.72 |
| Cashand Short Term Investments | 2.37 | 0.5 | 0.57 |
| Total Receivables Net | 63.14 | 78.19 | 65.19 |
| Deferred Income Tax | 12.87 | 10.74 | 12.04 |
| Accounts Receivable-Trade Net | 61.34 | 68.95 | 51.5 |
| Property/Plant/Equipment Total-Net | 278.11 | 232.2 | 229.29 |
| Minority Interest | 16.01 | 15.49 | 16.82 |
| Total Current Liabilities | 156.28 | 142.07 | 144.56 |
| Total Inventory | 79.82 | 70.39 | 86.92 |
| Accounts Payable | 61.41 | 53.27 | 59.13 |
| Other Currentliabilities Total | 35.1 | 22.03 | 19.74 |
| Total Long Term Debt | 50.77 | 20.01 | 35.54 |
| Intangibles Net | 0.03 | 0.05 | 0.05 |
| Other Long Term Assets Total | 9.72 | Not available | Not available |
| Total Current Assets | 163.11 | 150.57 | 155.27 |
| Capital Lease Obligations | 0.81 | 1.74 | 2.39 |
| Accumulated Depreciation Total | Not available | -80.16 | -66.05 |
| Accrued Expenses | Not available | 0.36 | 0.51 |
| Prepaid Expenses | Not available | 0.48 | 1.67 |
| Property/Plant/Equipment Total-Gross | Not available | 311.96 | 289.34 |
| Notes Payable/Short Term Debt | Not available | 50.46 | 46.76 |
| Note Receivable-Long Term | Not available | 7.13 | 5.87 |
| Short Term Investments | Not available | Not available | 0 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio1.86
Price to Sale Ratio1.43
Growth
Debt 5Yr CAGR %11.31
Margins
Operating Margin 12m8.4
Operating Margin 5y Avg7.13
Net Profit Margin 12m5.33
Net Profit Margin 5y4.82
Yield
Dividend Yield %0.1
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskExtreme risk
Board Risk66.54
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,939.15 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,375 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,985.3 | 1.69 L | 72.73 | — |
| Cipla | INR 1,408.9 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,118.75 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 72.11%
- FII
- 0.03%
- Other
- 27.89%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Hybrid Financial Services Ltd leads losers in 'B' group - Business StandardMarket news · 22 Jun 2026, 3:31 pm
Hybrid Financial Services Ltd leads losers in 'B' group Business Standard
Haleos Labs closes trading window from July 1 until Q1FY27 results - scanx.tradeMarket news · 18 Jun 2026, 1:33 pm
Haleos Labs closes trading window from July 1 until Q1FY27 results scanx.trade
Haleos Labs reports zero share encumbrance by promoters in FY26 - scanx.tradeMarket news · 13 Jun 2026, 12:26 am
Haleos Labs reports zero share encumbrance by promoters in FY26 scanx.trade
Haleos Labs Limited is Rated Sell - Markets MojoMarket news · 10 Jun 2026, 11:40 am
Haleos Labs Limited is Rated Sell Markets Mojo
HALEOS LABS LIMITED Share Price Today - Live HALEOSLABS Stock Price for NSE/BSE - UpstoxMarket news · 5 Jun 2026, 12:30 pm
HALEOS LABS LIMITED Share Price Today - Live HALEOSLABS Stock Price for NSE/BSE Upstox
Haleos Labs Limited is Rated Hold by MarketsMOJO - Markets MojoMarket news · 5 Jun 2026, 5:55 am
Haleos Labs Limited is Rated Hold by MarketsMOJO Markets Mojo
Corporate actions
Events
- dividendRs.1.5000 per share(15%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.5000 per share(15%)Dividend
- board MeetingsQuarterly Results & A.G.M.
Rusaka Markets Community
Discussion and sentiment for Haleos Labs
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Haleos Labs Limited, formerly, SMS Lifesciences India Limited, is an India-based company that is engaged in the business of manufacturing of active pharma ingredients (API) and their intermediates. The Company's API products include Ranitidine Hydrochloride (Form-2) USP / Ph. Eur / IP, Famotidine USP / Ph. Eur / IP, Sildenafil Citrate USP / Ph. Eur / IP, Allopurinol USP / EP / IP, Ropivacaine Hydrochloride USP / EP / IP, Dapsone USP/ EP /BP, Sibutramine Hydrochloride USP, Itraconazole USP / Ph. Eur, Fosphenytoin Sodium USP, Domperidone / Domperidone Maleate EP / IP, Brinzolamide, Tiagabine, Fosaprepitant and Albendazole, among others. Its intermediate offerings include Ranitidine HCl Intermediates, Rizatriptan Intermediates and Imidapril Intermediates. The Company's manufacturing facilities are located at Kazipally and Jeedimetla, and its research and development center is at Sanath Nagar in Hyderabad. The Company's wholly owned subsidiary is Mahi Drugs Private Limited.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- HALEOSLABS
- BSE Code
- 540679
Questions
Stock FAQ
What is the symbol and ISIN of Haleos Labs?
Haleos Labs has the symbol HALEOSLABS and ISIN - INE320X01016.
What is the current price of Haleos Labs?
Haleos Labs is currently trading at INR 1,558.70.
What are the year high and year low of Haleos Labs?
Haleos Labs has a year high of INR 1,778.35 and a year low of INR 1,050.05.
What is the market capitalization of Haleos Labs?
Haleos Labs has a market capitalization of INR 475.82 crore.
What is the P/E ratio of Haleos Labs?
Haleos Labs has a P/E ratio of 16.55.
What is the dividend yield of Haleos Labs?
Haleos Labs has a dividend yield of 0.10%.
How is the financial performance of Haleos Labs based on revenue, net income, and EPS?
Haleos Labs has revenue of INR 333.79 crore, net income of INR 17.31 crore, and EPS of INR 57.27.
What is the book value of Haleos Labs?
Haleos Labs has a book value of INR 706.25.
What is the debt-to-equity ratio of Haleos Labs?
Haleos Labs has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Haleos Labs?
Haleos Labs has a price-to-book ratio of 2.21 and a price-to-sales ratio of 1.43.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.